Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with retinoic acid in malignant melanoma.

被引：0
|
作者：
Kato, Y
Wang, XF
Qian, DZ
Wei, YF
Zhang, L
Atadja, P
Pili, R
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6253S / 6253S
页数：1
相关论文
共 50 条
  • [1] Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
    Kato, Yukihiko
    Salumbides, Brenda C.
    Wang, Xiao-Fei
    Qian, David Z.
    Williams, Simon
    Wei, Yongfeng
    Sanni, Tolib B.
    Atadja, Peter
    Pili, Roberto
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 70 - 81
  • [2] Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
    Mei, Qinglang
    Xu, Xiaohan
    Gao, Danling
    Xu, Yuting
    Yang, Jinbo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [3] Enhancing radiation response in malignant gliomas with the histone deacetylase (HDAC) inhibitor LAQ824
    Chinnaiyan, P
    Ray, S
    Harari, PM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S484 - S485
  • [4] Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
    Chen, LW
    Meng, SS
    Wang, H
    Bali, P
    Bai, WL
    Li, BY
    Atadja, P
    Bhalla, KN
    Wu, J
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) : 1311 - 1319
  • [5] Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
    Vo, Dan D.
    Prins, Robert M.
    Begley, Jonathan L.
    Donahue, Timothy R.
    Morris, Lilah F.
    Bruhn, Kevin W.
    de la Rocha, Pilar
    Yang, Meng-Yin
    Mok, Stephen
    Garban, Hermes J.
    Craft, Noah
    Economou, James S.
    Marincola, Francesco M.
    Wang, Ena
    Ribas, Antoni
    CANCER RESEARCH, 2009, 69 (22) : 8693 - 8699
  • [6] Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
    Rosato, RR
    Almenara, JA
    Maggio, SC
    Atadja, P
    Craig, R
    Vrana, J
    Dent, P
    Grant, S
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (11) : 1772 - 1785
  • [7] The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells
    Schwarz, Kerstin
    Romanski, Annette
    Puccetti, Elena
    Wietbrauk, Sarah
    Vogel, Anja
    Keller, Maren
    Scott, Jeffrey W.
    Serve, Hubert
    Bug, Gesine
    LEUKEMIA RESEARCH, 2011, 35 (01) : 119 - 125
  • [8] The histone deacetylase inhibitor LAQ824 is selectively toxic to tumor cell lines including multidrug resistant cells
    Atadja, P
    Remiszewski, L
    Trogani, N
    Walker, H
    Hsu, M
    Gao, L
    Yeleswarapu, L
    Perez, L
    Cohen, P
    Lassota, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S103 - S103
  • [9] Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages through Transcriptional Regulation of IL-10
    Wang, Hongwei
    Cheng, Fengdong
    Woan, Karrune
    Sahakian, Eva
    Merino, Oscar
    Rock-Klotz, Jennifer
    Vicente-Suarez, Ildefonso
    Pinilla-Ibarz, Javier
    Wright, Kenneth L.
    Seto, Edward
    Bhalla, Kapil
    Villagra, Alejandro
    Sotomayor, Eduardo M.
    JOURNAL OF IMMUNOLOGY, 2011, 186 (07): : 3986 - 3996
  • [10] A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
    Yamamoto, S
    Aiken, T
    Kaneda, Y
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6250S - 6251S
12345